PhD: Modelling CHO clonal phenotype variance for optimal bioprocessing platform design

A 4-year iCASE PhD Studentship between Biopharm Process Research at GSK (Stevenage) and the University of Kent.
The project will use advanced screening, genome editing (e.g. CRISPR/Cas9)/synthetic biology and analytical technologies, to further develop an understanding of the cellular processes that limit and underpin cell metabolism, cell growth, recombinant protein product yield and quality. In turn, this understanding will be used to develop new CHO cell chassis and bioprocesses that enhance GSKs ability to rapidly generate cell lines making novel molecules at appropriate amounts and quality for investigation and progression towards clinical studies. The project will involve secondment to the GSK Stevenage site to undertake sections of the work.
This is an excellent opportunity for a student to work with two world-class institutions to investigate cell biology, bioprocessing and recombinant protein production and be involved in the translation of the findings of research into industrial application.
Applications will be considered until the deadline of 16th April 2018. Interviews will be held at the GSK Stevenage site in the week of 23rd April 2018.
More details: